3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Reports Second Quarter 2026 Financial Results
Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
Announces Closing of Convertible Senior Notes Offering
Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
Material disclosure
Merger Agreement Between Ligand Pharmaceuticals and XOMA Royalty
Reports First Quarter 2026 Financial Results
Termination of TR-Beta Program - Ligand Pharmaceuticals Notifies Viking
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus Filed Pursuant to Rule 425
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Amended Notice of Proposed Sale of Securities